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Abstract
Background: Surgery is the definitive treatment of Cushing’s syndrome (CS) but medications may also be used 
as a first-line therapy. Whether preoperative medical treatment (PMT) affects postoperative outcome remains 
controversial.
Objective: (1) Evaluate how frequently PMT is given to CS patients across Europe; (2) examine differences in 
preoperative characteristics of patients who receive PMT and those who undergo primary surgery and (3) determine if 
PMT influences postoperative outcome in pituitary-dependent CS (PIT-CS).
Patients and methods: 1143 CS patients entered into the ERCUSYN database from 57 centers in 26 countries. Sixty-
nine percent had PIT-CS, 25% adrenal-dependent CS (ADR-CS), 5% CS from an ectopic source (ECT-CS) and 1% were 
classified as having CS from other causes (OTH-CS).
Results: Twenty per cent of patients took PMT. ECT-CS and PIT-CS were more likely to receive PMT compared to 
ADR-CS (P < 0.001). Most commonly used drugs were ketoconazole (62%), metyrapone (16%) and a combination of 
both (12%). Median (interquartile range) duration of PMT was 109 (98) days. PIT-CS patients treated with PMT had 
more severe clinical features at diagnosis and poorer quality of life compared to those undergoing primary surgery 
(SX) (P < 0.05). Within 7 days of surgery, PIT-CS patients treated with PMT were more likely to have normal cortisol 
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(P < 0.01) and a lower remission rate (P < 0.01). Within 6 months of surgery, no differences in morbidity or remission 
rates were observed between SX and PMT groups.
Conclusions: PMT may confound the interpretation of immediate postoperative outcome. Follow-up is recommended 
to definitely evaluate surgical results.
Introduction
Surgery is the first-line treatment in patients with 
Cushing’s syndrome (CS), but preoperative medical 
therapy (PMT) is often given, in order to control cortisol 
excess and correct severe comorbidities prior to the 
surgical procedure (1, 2). PMT may also be used in those 
centers where, for any reasons (e.g. long waiting time for 
surgery, limited availability of a specialized surgeon, etc.), 
surgical intervention cannot be performed soon after 
diagnosis of CS (2).
It has been hypothesized that patients with Cushing’s 
disease (CD) preoperatively treated with adrenal-directed 
medications (i.e. steroidogenesis inhibitors) might have 
a lower risk of intraoperative bleeding, and therefore, a 
better surgical outcome but no firm data confirm this 
hypothesis (1, 3). Clinical observation suggests that 
PMT may protect CD patients from the occurrence of 
hypoadrenalism in the immediate postsurgical period, 
an important information that is actually considered as 
the gold standard to diagnose remission of the disease 
(4, 5). However, PMT may also confound the correct 
interpretation of outcome early after transsphenoidal 
surgery due to the ‘de-repression’ of the normal 
corticotroph cells in the remaining pituitary gland (4, 6). 
As a matter of fact, data on the potential, beneficial impact 
of PMT on perioperative morbidity and the immediate 
surgical and long-term outcomes in CD patients are scant 
and inconclusive (3, 7, 8).
The ERCUSYN is the largest prospective database 
existing to date which collects information on diagnosis, 
management and long-term follow-up in CS (9). Because 
ERCUSYN includes data from 57 centers in 26 European 
countries, it reflects the ‘real-life’ clinical practice and 
allows ascertaining whether and how PMT is used before 
surgery across Europe.
The aims of this study where to (1) evaluate the 
prevalence of preoperative medical treatment (PMT) in CS 
patients throughout Europe; (2) determine any differences 
in preoperative characteristics of patients who receive 
PMT and those who undergo surgery directly (SX) and 
(3) determine if PMT influences postoperative outcome in 
patients with pituitary-dependent CS (PIT-CS).
Patients and methods
Description of the database
One-thousand three hundred forty-one patients with 
Cushing’s syndrome (CS), included into the ERCUSYN 
database between January 1, 2000 and January 31, 2016, 
were analyzed (10). Patients were classified into four 
major groups: pituitary-dependent CS (PIT-CS), adrenal-
dependent (ADR-CS; adrenal adenoma), CS from an 
ectopic source (ECT-CS) and CS from other etiologies 
(OTH-CS).
A detailed description of the database layout has been 
provided elsewhere (9). This study has interrogated data 
entered in the ‘Diagnosis’, ‘Therapy’ and ‘First follow-up 
visit’ sections.
The ‘Diagnosis’ section contains information at 
diagnosis: baseline demographic and anthropometric 
characteristics, etiology of CS and diagnosis date, delay 
between onset of symptoms and final diagnosis of CS, 
other specialists consulted for Cushing’s symptoms 
before correct diagnosis, clinical features, comorbidities, 
bone status and two questionnaires on quality of life 
(CushingQoL and EuroQoL-5D). It also contains a 
subsection comprising diagnostic tests; for each of 
them, hormone concentrations, units and diagnostic 
interpretation (‘supporting’ or ‘not supporting’ the 
diagnosis) is required.
The ‘Therapies’ section includes specific information 
on any treatment received (medical, surgery, radiotherapy). 
In the ‘medical treatment’ section, participants are asked 
to enter information on any medication specifically 
used to treat hypercortisolism before surgery, including 
ketoconazole, metyrapone, cabergoline, mitotane, 
mifepristone, etomidate and aminogluthetimide. Starting 
and final date of medical treatment as well as starting and 
final dose of each drug is also required.
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The ‘Surgery’ section contains information on date 
and type of procedure, histology report and the clinical/
biochemical outcome in the immediate, postoperative 
period. In particular, participants are requested to 
indicate, when available, the clinical status early (within 
7  days) after surgery, by choosing between the options 
‘no benefit’ or ‘cure/remission’. Parameters on which 
outcome judgment was made were also asked for, namely 
‘serum/urine cortisol’ (‘low’, ‘normal’, ‘high’), ‘clinical 
improvement’ (‘yes’, ‘no’) and ‘need for glucocorticoids’ 
(‘yes’, ‘no’). ‘Low’ cortisol levels refer to those values, 
which are below the lowest limit of the normal range 
on the assay used in each center. ‘Normal’ cortisol 
levels refer to values within the normal range. ‘Clinical 
improvement’ refers to recovery characteristics early – 
within the first week – after surgery (subjective well-being 
of patients, and prevalence of perioperative morbidity). 
The ‘Follow-up visit’ section contains several biochemical 
testing, including morning serum cortisol and overnight 
1-mg dexamethasone suppression test (DST). Centers 
are asked to provide information on both the value of 
hormone measurement and its diagnostic interpretation, 
i.e., ‘low’, ‘normal’, ‘high’, according to whether the value 
is below, within or above the normal range of the assay 
used in each center. In this study, the cut-offs of 5 µg/
dL (138 nmol/L) has been used for both morning serum 
cortisol and serum cortisol after an overnight DST (5).
Glucocorticoid replacement was withdrawn at least 
24 h prior to cortisol evaluation at any time points. The 
patient’s surgical outcome (‘active hypercortisolism’ 
or ‘remission/cure’) assessed at first visit after surgery 
is also collected. ‘First visit after surgery’ refers to 
the first visit performed after 7 and up to 180  days 
after surgical intervention (7, 11). In this time frame, 
patients did not receive any additional treatment for CS. 
Comorbidities are also collected, including hypertension, 
thromboembolism, hypopituitarism, dyslipidaemia, 
diabetes mellitus, cardiovascular diseases, osteoporosis, 
fractures and depression.
If a specific item is not available, participants are asked 
to select ‘not answered’ (i.e. when information was missing) 
or ‘not known’ (when a test or clinical evaluation had been 
performed but results were not available for any reason).
The ERCUSYN study was approved by the ethics 
committee (CEIC) of the Hospital Sant Pau, Barcelona, 
Spain, which is the coordinating center. In addition, 
the local ethics committee approval was obtained for 
each participating institution and all patients gave their 
written informed consent, depending on national legal 
requirements.
All the data reported into the system were carefully 
monitored for inconsistencies, queried when necessary 
and validated before statistical analysis.
Statistical analysis
SPSS for Windows, version 22.0 (SPSS) was used to perform 
data analysis. Data on blood pressure and QoL scores are 
expressed as mean ± s.d., all the other values, not normally 
distributed, are expressed as median (interquartile range, 
IQR). Comparison between two groups was carried out 
using the Mann–Whitney’s U test or the Student’s t-test 
(depending on data distribution) for quantitative variables, 
and the χ2 for categorical variables. The diagnostic 
performance of the tests was compared calculating the 
likelihood ratio from contingency tables; significance 
was identified using the adjusted residual. Stepwise 
logistic regression was used to identify clinical variables 
and type of treatment – PMT or SX – that might predict 
cortisol levels and outcome in the immediate – 7 days – 
postoperative period as well as at first postoperative visit 
within 180 days of surgery, in PIT-CS patients. Statistical 
significance was defined as a two-tailed P value <0.05.
Results
General characteristics of the overall population
Of 1341 patients included, 904 (67%) had PIT-CS, 335 
(25%) had ADR-CS, 80 (6%) had ECT-CS and 22 (2%) 
had OTH-CS. Specific etiologic information has been 
described in detail elsewhere (10). Briefly, 79% of patients 
were women, median age was 44  years (IQR, 21  years), 
and median time elapsed from clinical onset to diagnosis 
was 2 years (IQR, 3 years) (10).
First-line treatment
Of 1341 patients included, 1143 had information 
available on treatment (85%). Eight hundred and ninety-
three (78%) underwent surgery without receiving prior 
medical treatment (SX group), while 226 (20%) took 
presurgical medical treatment (PMT group). Twenty-four 
(2%) additional patients received medical treatment only, 
without subsequent intervention and, therefore, were 
excluded from the analysis. Distribution of each modality 
of treatment according to CS etiology is shown in Table 1.
ADR-CS patients were more likely to undergo surgery 
as a first-line treatment in comparison to both PIT-CS and 
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ECT-CS (262/281 (93%) for ADR-CS vs 583/787 (74%) 
for PIT-CS and 33/59 (56%) for ECT-CS; P < 0.001). Both 
PIT-CS (184/787 (23%) and ECT-CS patients (22/59 (37%)) 
were more likely to receive PMT compared to ADR-CS 
(19/281 (7%); P < 0.001) (Table 1). Countries where PMT 
was more frequently used in PIT-CS patients were the 
Netherlands (52%), Spain (41%), UK (39%), Russia (27%) 
and France (15%).
Characteristics of PMT: type, dose and duration
Two hundred and twenty-six CS patients (20%) were 
treated with PMT. Data on dose and duration of each 
treatment modalities are shown in Table 2. Most patients 
(142/226 (63%)) were preoperatively treated with KTZ 
alone, of whom 80% were PIT-CS, 11% ECT-CS and 9% 
ADR-CS. MTP alone was administered to 36 patients 
(16%), of whom 85% had PIT-CS, 9% ADR-CS and 6% 
ECT-CS. All 14 (6%) patients taking CAB had PIT-CS. MIF 
was taken by five patients, 4 with ECT-CS and 1 with 
PIT-CS.
The combination of KTZ and MTP was used in 28 
(12%) patients, of whom 82% had PIT-CS, 11% ADR-CS 
and 7% ECT-CS. Combination of KTZ and CAB was 
administered to 12 (5%) patients, most with PIT-CS 
(92%). The combination of KTZ and MIF was taken by 5 
patients, 3 with PIT-CS and 2 with ECT-CS. Combination 
of KTZ and either mitotane or aminoglutethimide was 
used in 2 PIT-CS patients. CAB or mitotane was added to a 
combination of KTZ and MTP in 2 PIT-CS patients.
Median (IQR) duration of PMT was 107 (98) days. No 
differences in maximum dose, mean dose and duration of 
treatment for any of the medications were found between 
the etiologic groups.
Preoperative characteristics
PIT-CS patients who received PMT had worse baseline 
clinical features as compared with those in the SX group 
(Fig.  1). In particular, the PMT group had higher mean 
(±s.d.) systolic and diastolic blood pressure than the SX 
group (145 ± 21 vs 139 ± 21 mmHg for systolic, P = 0.001; 
90 ± 15 vs 86±14 mmHg for diastolic, P = 0.002) (Fig. 1A). 
Prevalence of some hypercortisolism-related characteristics 
was greater in the PMT than in the SX group, including skin 
alterations (easy bruising, purple striae) (145/173 (84%) 
Table 1 Distribution of treatment modalities based on CS etiology.
Treatment group PIT-CS ADR-CS ECT-CS OTH-CS Overall
Only surgery (SX) 583 (74) 262 (93)* 33 (56) 15 (94) 893 (78)
Presurgical medical treatment (PMT) 184 (23)** 19 (7) 22 (37)** 1 (6) 226 (20)
Only medical treatment (MT) 20 (3) 0 4 (7)* 0 24 (2)
Overall 787 281 59 16 1143
Percentages are shown in parenthesis.
*P < 0.001 vs PIT-CS and ECT-CS; **P < 0.001 vs ADR-CS.
ADR-CS, adrenal-dependent CS; CS, Cushing’s syndrome; ECT-CS, CS from an ectopic source; OTH-CS, CS from other etiologies; PIT-CS, pituitary-dependent CS.
Table 2 Type and dose of medications (single or in combination), and duration of medical treatment in 226 patients treated 
prior to surgery.
Type n (%) Maximum dose (mg/day)* Mean dose (mg/day)* Duration (days) CUD (g)**
Single medication
 KTZ 142 (63) 600 (200) 600 (200) 97 (82) 51 (64)
 MTP 36 (16) 1250 (1250) 1062 (917) 114 (129) 104 (195)
 CAB 14 (6) 1 (0.65) 0.8 (0.5) 109 (193) 96 (224)
 MIF 5 (2) 600 (100) 600 (100) 42 (188) 34 (112)
Combined medication
 KTZ + MTP 28 (12) KTZ 600 (400) KTZ 600 (275) KTZ 88 (145) KTZ 37 (82)
MTP 1500 (1250) MTP 1453 (750) MTP 101 (200) MTP 126 (204)
 KTZ + CAB 12 (5) KTZ 700 (350) KTZ 650 (350) KTZ 113 (258) KTZ 43 (157)
CAB 0.5 (0.5) CAB 0.5 (0.5) CAB 93 (54) CAB 47 (146)
 KTZ + MIF 5 (2) KTZ 800 (400) KTZ 800 (400) KTZ 109 (311) KTZ 108 (243)
MIF 400 (200) MIF 400 (100) MIF 35 (373) MIF 14 (221)
Doses and duration are shown as median (interquartile range, IQR).
*Dose for cabergoline (CAB) is expressed as mg/week; **CUD for CAB is expressed as mg.
CAB, cabergoline; CUD, cumulative dose; KTZ, ketoconazole; MIF, mifepristone; MTP, metyrapone.
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vs 412/544 (76%); P = 0.026), muscle atrophy/weakness 
(126/163 (77%) vs 331/497 (67%); P = 0.010), hair loss (in 
women) (46/96 (48%) vs 100/334 (30%); P = 0.001) and 
hirsutism (in women) (92/118 (78%) vs 260/411 (63%); 
P = 0.003) (Fig.  1B). Mean (±s.d.) CushingQoL score was 
also lower in the PMT than the SX group, consistent with 
poorer quality of life in the former (36 ± 1 vs 42 ± 17, 
respectively; P = 0.035) (Fig. 1C).
Data on pituitary imaging in PMT vs SX patients are 
shown in Table 3. PMT patients (51 of 171 (30%)) were 
more likely to have a negative MRI compared to SX 
patients (103 of 517 (20%)) (P = 0.031).
No differences in the preoperative characteristics were 
found in the other etiologic groups.
Immediate postoperative evaluation in PIT-CS 
patients treated with steroidogenesis inhibitors 
as PMT
In the immediate postoperative period (within 7 days of 
surgery), ‘cure’ or ‘remission’, as defined by the ERCUSYN 
partners, was more frequently reported in PIT-CS patients 
who underwent SX as the only treatment as compared 
with patients who took steroidogenesis inhibitors 
(ketoconazole, metyrapone, mitotane) (344/459 (75%) 
vs 108/176 (61%); P = 0.003). Patients who received SX 
were more likely to be classified as being in remission 
as compared with those who took PMT (OR 1.86 (95% 
CI 1.16–2.96); P = 0.009). This significance remained 
after adjusting for preoperative features (skin alterations 
and muscle weakness), adenoma size, visualization of a 
pituitary adenoma on MRI and histology confirmation of 
an adenoma (P = 0.046).
As expected, PIT-CS patients who received PMT were 
more frequently reported to have cortisol levels within the 
‘normal’ range as compared with the SX group (40/176 
(23%) vs 56/448 (13%); P = 0.006). On the other hand, 
low or undetectable cortisol levels were more frequently 
reported in SX patients as compared with PMT patients 
(307/448 (69%) vs 106/176 (60%); P = 0.010).
SX patients were more likely to have low/undetectable 
cortisol levels early after surgery compared to the PMT 
group (OR 0.48 (95% CI 0.30–0.76); P = 0.002). This 
significance remained after adjusting for preoperative 
features (skin alterations and muscle weakness), adenoma 
Figure 1
Preoperative clinical characteristics in PIT-CS patients who 
received presurgical medical treatment (PMT) and PIT-CS 
patients who were operated on without prior medical therapy 
(SX). (A) Systolic and diastolic blood pressure in PMT vs SX 
patients. *P < 0.01, indicating more elevated systolic and 
diastolic blood pressure in PMT vs SX (145 ± 21 vs 
139 ± 21 mmHg and 90 ± 15 vs 86 ± 14 mmHg, respectively). (B) 
Clinical features in PMT vs SX patients. *P < 0.05, indicating 
greater prevalence of hypercortisolism-related features in 
PMT as compared with SX. (C) Quality of life (QoL), as 
measured using the CushingQoL questionnaire, in PMT vs SX 
patients. *P = 0.035, indicating worse QoL in PMT than SX 
(35.6 ± 17.3 vs 42 ± 1, respectively).
Table 3 Pituitary imaging in 688 PIT-CS patients receiving 
either PMT or SX.
MRI finding PMT (n = 171) SX (n = 517) P value
Not seen 51 (30) 103 (20) 0.031
Microadenoma 84 (57) 295 (49) 0.093
Macroadenoma 36 (23) 119 (21) 0.67
Percentages are expressed in parenthesis.
MRI, magnetic resonance imaging; PMT, preoperative medical therapy; 
SX, surgery.
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size, visualization of a pituitary adenoma on MRI and 
histology confirmation of an adenoma (P = 0.017).
Postoperative clinical improvement was more 
frequently reported in SX than in PMT patients (351/423 
(83%) vs 123/161 (76%) (P = 0.040)).
First postoperative evaluation within 180 days of 
surgery in PIT-CS patients treated with 
steroidogenesis inhibitors as PMT
The first postoperative visit after discharge from the 
hospital (>7 days after surgery) was performed within the 
selected period of 180 days in 723 patients. Mean (±s.d.) 
time for this visit was 96.3 ± 84.2  days. In comparison 
to the observations within the first week after surgery, 
no difference in the prevalence of remission was found 
between SX (508/548 (93%)) and PMT (156/174 (90%)) 
patients; P = 0.21. Prevalence of cortisol elevation above 
5 µg/dL (138 nmol/L) after overnight 1-mg DST was 
slightly greater in the PMT than in the SX (19/30 (63%) 
vs 21/72 (29%); P = 0.048). When the cut-off of 1.8 µg/dL 
(50 nmol/L) was evaluated, no differences in the 
responsiveness of cortisol were observed between the two 
groups.
No differences in the prevalence of postsurgical 
morbidities, including thromboembolism and 
hypopituitarism, were observed at first post-discharge 
evaluation, between the PMT and SX groups.
When patients with normal cortisol levels immediately 
after the intervention were analyzed, 42 of 56 (75%)in 
the SX group vs 32 of 40 (80%) PMT patients (P = 0.27) 
received further treatment within 180 postoperative days. 
Remission rate at first postsurgical visit was similar in 
both groups (26% for SX vs 25% for PMT; P = 0.81) (Fig. 2).
Relationship between dose or duration of PMT and 
immediate postoperative outcome
A relationship between dose/duration of PMT and 
postoperative outcome could only be found for MTP. 
Thirty-six PIT-CS patients were treated with MTP alone and 
twenty-eight with MTP in combination with other drugs.
Median (IQR) cumulative dose (CUD) of MTP was 
significantly greater in patients with cortisol levels 
within the normal range (n = 21 with data available) as 
compared with those having hypocortisolism (n = 29) 
in the immediate postoperative period (223 (269) vs 72 
(141) g; P = 0.017). Similarly, patients classified as being 
surgical failures (n = 18) received greater CUD of MTP as 
compared with those in remission (n = 34) (223 (210) vs 
95 (138) g; P = 0.026), which might be a reflection of more 
severe disease.
Perioperative mortality
In the whole series, perioperative mortality (within one 
month of surgery) was not different in SX as compared 
with PMT group. Of 7 patients who died within one month 
of surgery, 4 (57%) received SX as a first-line treatment 
and the remaining three (43%) took PMT (P = 0.29).
Discussion
These ERCUSYN data show that in Europe, one out of every 
five patients with Cushing’s syndrome (CS) undergoes 
preoperative administration of steroidogenesis inhibitors 
prior to surgery (mostly ketoconazole, metyrapone or a 
combination of both) and, to a lesser extent, dopamine 
agonists (e.g. cabergoline) and glucocorticoid receptor 
antagonists (e.g. mifepristone). However, use varies in 
different countries, ranging from 52% in The Netherlands 
to no use in nine countries and depending on the 
underlying cause, being more frequently prescribed in 
Figure 2
Outcome in 96 patients who had ‘normal’ cortisol levels in the 
immediate postoperative period (<7 days), within 180 
postsurgical days. SX, surgery; PMT, preoperative medical 
treatment. To calculate the remission rate in each group, 
patients who underwent second-line medical therapy or 
radiotherapy (10 patients in the SX and 12 in the PMT group) 
were excluded. No differences were found in the rate of 
patients who underwent further treatment as well as in the 
remission rate between SX and PMT group (P = 0.27 and 
P = 0.81, respectively).
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patients with an ectopic (ECT-CS) (37%) or pituitary source 
(PIT-CS) (23%), than in ADR-CS (7%). Patients with more 
florid hypercortisolism at diagnosis and proteocatabolic 
signs, such as muscle atrophy and skin alterations, and 
more impaired quality of life, were more likely to receive 
PMT than those with a less aggressive clinical presentation. 
Thus, although we cannot exclude that some clinicians 
were prompted to use PMT due to long waiting time for 
surgery in their own center, our results suggest that most 
ERCUSYN participants tended to pretreat those patients 
with more severe hypercortisolism, attempting to control 
their comorbidities before undergoing the intervention.
Up to now, there is little evidence that PMT affects 
postsurgical outcome. On the one hand, those who 
defend its use argue that if hypercortisolism is treated, 
it will improve comorbidities and the patient’s clinical 
condition, especially in severe disease, so that surgery 
is performed in more favorable conditions, potentially 
lowering the risk of perioperative complications (3, 6, 8, 
12, 13, 14, 15, 16, 17, 18, 19, 20, 21).
On the other hand, immediate evaluation in the first 
week after surgery to identify whether a patient is ‘cured/
in remission’, as suggested in some guidelines (5), may be 
affected by PMT. Compared to patients who go directly 
to surgery, which remains the first-choice therapeutic 
option to quickly correct cortisol excess in CS (5), in PMT 
patients, clinical/biochemical improvements will more 
frequently have begun before surgery, so changes that take 
place in the first week after surgery may be less dramatic. 
This seems to be the case, since patients who underwent 
surgery without taking PMT were more likely to be 
classified as being ‘in remission’, compared to those who 
took PMT, in whom further clinical improvement was less 
evident in the immediate postoperative period. In fact, 
the PMT group was more likely to have ‘normal’ cortisol 
levels in the first week after adenoma resection than their 
counterparts treated with surgery as a first-line therapy. 
For the first time, this finding supports the hypothesis 
that PMT may protect from cortisol suppression in the 
immediate postoperative period (4). Based on clinical 
observations, it has been suggested that a sustained 
cortisol normalization induced by steroidogenesis 
inhibitors in the preoperative period may ‘de-repress’ 
the healthy corticotroph cells in the pituitary (whose 
function is suppressed by longstanding hypercortisolism), 
thus avoiding hypoadrenalism early after surgery (4). A 
few, small studies have been published to date on this 
topic, mostly retrospective, showing similar cortisol levels 
in the immediate postsurgical period, between patients 
who reached eucortisolism after PMT with steroidogenesis 
inhibitors and those who did not (7, 8, 22). Conversely, 
one report described postoperative cortisol suppression 
in 13 patients who had achieved eucortisolism after PMT, 
raising the hypothesis that pretreatment with adrenal-
blocking agents may ameliorate intraoperative conditions 
(e.g. reduced bleeding), facilitating total adenoma 
resection and postoperative ACTH deficiency (3).
Additionally, postoperative ‘normalization’ of cortisol 
is generally considered a marker of persistent disease and 
a solid predictor of possible recurrence, although there is 
not widespread agreement on this point (22, 23, 24, 25, 
26, 27). Although it is likely that most of the ERCUSYN 
participants relied upon the occurrence of hypoadrenalism 
to define early remission, establishing it with certainty 
is not possible due to the lack of a unique, standardized 
method for cortisol measurement throughout the centers. 
However, we have found that both ‘normal’ cortisol 
levels and a lower rate of early remission within 7 days 
of surgery, as described qualitatively, are associated with 
the administration of PMT with steroidogenesis inhibitors 
in PIT-CS, regardless of factors previously associated with 
surgical outcome, including adenoma size, visualization of 
a pituitary adenoma on MRI and histology confirmation 
(22, 28, 29, 30).
Of note, lack of visualization of an adenoma was more 
frequently reported in PIT-CS patients who received PMT 
as compared with those who were primarily operated on. 
This suggests that, in some cases, cortisol-lowering drugs 
have been offered within a ‘wait and see’ approach, when 
a successful resection of a nonvisible ACTH-secreting 
pituitary tumor was considered difficult to achieve early 
after the diagnosis of hypercortisolism (29). However, 
time interval between diagnosis of cortisol excess and 
surgery was similar between the two groups, indicating 
that starting PMT did not ‘delay’ the intervention in the 
ERCUSYN PIT-CS patients.
Clearly, PMT is highly recommendable in cases of an 
occult ectopic source of ACTH, in order to treat acute and 
potentially life-threatening morbidities associated with 
severe hypercortisolism (5, 31, 32); nevertheless, similar 
baseline clinical characteristics and visualization rate of 
an ectopic tumor in ECT-CS taking PMT vs those who 
underwent primary surgery were observed, possibly due 
to the limited sample size of ERCUSYN patients with this 
etiology.
It is reassuring, however, and demonstrated for the 
first time, that at first postoperative visit within 6 months 
of surgery, no differences were observed between the PMT 
and direct SX groups, as far as prevalence of postsurgical 
morbidities or remission rates. Moreover, thromboembolism 
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was not more frequent in ERCUSYN patients with early 
postsurgical hypoadrenalism as compared with those 
having normal cortisol; these results are in line with 
previous observation that short-term medical therapy 
leading to biochemical remission does not improve the 
hypercoagulable state in CD patients (33). However, 
prevalence of thromboembolism may be underestimated 
in the ERCUSYN, depending upon intercentre differences 
in the monitoring strategy of postsurgical complications 
and different preventive protocols.
Clearly, many factors might influence this later 
postoperative outcome in PIT-CS patients, such as 
tumor size, invasion of local tissues, surgeon’s expertise, 
disease duration and genetic defects, any of which 
might, in turn, overcome the potential impact of PMT 
on the occurrence of remission (2). Because cortisol 
dynamics have been shown to vary widely over the 
first 6–12 postoperative weeks, potentially leading to 
delayed stabilization of cortisol levels, later biochemical 
evaluation is essential to reliably distinguish the ultimate 
outcome of transsphenoidal surgery (7, 8, 34). Our data 
demonstrating that PMT is a further confounding factor 
for the proper interpretation of early surgical outcome in 
PIT-CS patients has important implications for decisions 
regarding the timing of additional therapy. In fact, early, 
detectable levels of postoperative cortisol in PMT patients 
might be misinterpreted as reflecting surgical failure 
and prompt some clinicians to refer them for further 
treatment. Instead, our data clearly support the need for 
retesting and long-lasting follow-up in all PIT-CS patients 
undergoing TSS.
The ERCUSYN design does capture information on 
changes of cortisol levels in patients taking PMT, and so, we 
could not assess the efficacy of this therapeutic approach 
and quantify how many patients achieved presurgical 
eucortisolism with PMT. Previous studies reported that rate 
of control of hypercortisolism ranges from 45% to 93% in 
CS patients taking KTZ (3, 8, 13, 16, 18), and from 35% to 
72% in those treated with MTP (3, 8, 15, 21), depending 
on the assays used to define cortisol normalization, the 
maximum dose reached and genetically based differences 
in the individual responsiveness to these agents (35). 
Combination of both medications was reported to correct 
hypercortisolism in 45% of patients (8).
Limitations of this study include lack of both 
quantitative data and standardized methods to assess both 
presurgical and immediate postoperative biochemical 
status. This is due to both intra- and inter-centre differences 
in the assays used and lack of information on the normal 
range for each of them. Another limitation, which strictly 
pertains to the multicentric nature of ERCUSYN, is the 
heterogeneity in both the indications to use PMT and 
surgical success rate among the centers. While this may 
bias the results, it may also increase their external validity, 
allowing to generalize the conclusions and reflect real-life 
practice. Large, prospective, single-center studies should 
be performed to confirm the robustness of our data. In 
addition, ERCUSYN does not provide information on the 
safety of medications used as PMT or the effectiveness 
of such an approach to adequately reduce cortisol 
levels. Finally, variable time interval from surgery to 
first postoperative assessment among patients may have 
limited the detection of postoperative morbidity.
In conclusion, our study on 1143 CS patients entered 
in the ERCUSYN database has shown that cortisol-lowering 
medications are used, as a first-line treatment, in 20% of 
patients across Europe. Use of adrenal-blocking agents 
prior to pituitary surgery is independently associated with 
higher rate of cortisol ‘normalization’ and lower probability 
of hypoadrenalism, and consequently lower immediate 
postoperative identification of remission, compared 
to patients who go directly to surgery. Thus, caution is 
warranted when interpreting immediate postoperative 
status of PMT patients. However, at first postoperative visit 
within 6 months of surgery, no differences in remission 
rates or morbidities were seen between PMT and SX 
patients. Thus, benefits of preoperative improvements 
of hypercortisolism and consequent comorbidities 
attained by PMT, that are still to be evaluated, have to 
be confronted with the desire of immediate postoperative 
assessment as a prognostic marker of patients’ longer term 
outcome, as suggested in current guidelines (5). However, 
long-term follow-up and repeated testing are still 
necessary in all patients, treated or not with PMT, in order 
to detect recurrences and conclusively establish surgical 
outcome and the most adequate long-term management 
strategy for each individual patient. A randomized trial 
assessing simple endpoints, such as length of hospital 
stay, surgical impression and adverse effects of surgery, 
is needed to conclusively demonstrate that PMT is a 
valid option in patients waiting for surgical correction of 
hypercortisolism.
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